Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-02-25
2010-02-02
Graser, Jennifer E (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S185100, C424S193100, C424S203100, C424S253100, C424S257100, C530S300000, C530S350000
Reexamination Certificate
active
07655240
ABSTRACT:
This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a Rho GTPase activator.
REFERENCES:
patent: 6660847 (2003-12-01), Shiozawa et al.
patent: 1 342 784 (2003-09-01), None
Ron et al (EMBO J. 1988. 7: 2465-2473),.
Komai et al (Bichem. Biophys. Res. Commun.2002. 299: 455-458).
Eva et al. (Proc, Natl. Acad. Sci USA 1988. 85: 2061-2065).
Smith et al (Nature. 1997. 388: 539-547).
Lan et al (Infect. Immun. 2003. 71: 6298-6306).
Bakshi et al (J.bacteriol. 2000. 182: 2341-2344).
Stender et al (Mol.Microbiol. 2000. 36: 1206-1221).
McClelland et al. 2001. Nature 413: 852-856.
Ehrbar et al (J.Baceteriol. 2003. 185: 6950-6967).
Mirold et al (2001. J. Mol. Biol. 2001. 312: 7-16).
Mirold et al. (Proc. Natl. Acad. Sci. USA. 1999. 96: 9845-9850).
Parkhill et al. (Nature. 2001. 413: 848-852).
Walker et al (Infect. Immun. 62: 3817-3828).
Parkhill/Sharp et al (Nat.Genet. 2003. 35: 32-40).
Pullinger et al (Infect. Immun. 1996. 64: 4163-4171).
Lockman et al (Infect. Immun. 2022. 70: 2708-2714).
Oswald et al (Proc. Natl. Acad. Sci. USA 1994. 91: 3814-3818).
Felmlee et al (J. Bacteriol. 163:94-105(1985).
Falbo et al Infect Immun. 1993. 61: 4909-4914).
Buetow et al Nat. Struct. Biol. 2001. 8:584-588).
Database UniProt ′(Online! Nov. 1, 1996, “Cytotoxic necrotizing factor 1.” Retrieved from EBI accession No. UNIPORT: Q47106.
Moreau Violaine et al: “Action can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA” Molecular and Cellular Biology, vol. 23, No. 19, Oct. 2003 pp. 6809-6822.
Munro P et al: “The Rho GTPase activators CNF1 and DNT bacterial toxins have mucosal adjuvant properties” Vaccine, Butterworth Scientific. Guildford, GB, vol. 23, No. 20, Apr. 8, 2005, pp. 2551-2556.
Anjuere Fabienne
Boquet Patrice
Czerkinsky Cecil
Flatau Gilles
Lemichez Emmanuel
Graser Jennifer E
Institut National de la Sante et de la Recherche Medicale (INSER
Young & Thompson
LandOfFree
Vaccine composition comprising an immunoadjuvant compound... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine composition comprising an immunoadjuvant compound..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition comprising an immunoadjuvant compound... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230116